High correlations between primary tumours and locoregional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18- fluoro-D-glucose uptake

Nguyen Xuan Canh1, Young So2, Jin-Haeng Chung3, Won Woo Lee4, So Yeon Park5, Sang Eun Kim5,
1 Cho Ray Hospital
2 Department of Nuclear Medicine, Konkuk University School of Medicine, Chungju, Republic of Korea.
3 Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
4 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
5 Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

Main Article Content

Abstract

SUMMARY


The purpose of the study was to investigate whether glucose transporter type 1 (Glut-1) mediated 2-deoxy-2-F18- fluoro-D-glucose (FDG) uptake of primary tumour is related to the likelihood of malignancy involvement in loco-regional lymph nodes (LNs) in 126 non-small-cell lung cancer (NSCLC) patients (M:F = 103:23, age = 65 ± 9.7 years). Maximum standardized uptake values (maxSUV) and Glut-1 expression levels (determined by PET and immunostaining, respectively) of primary tumours and PET positive loco-regional LNs were compared.
Significant correlations were found between malignant LNs and primary tumours with respect to maxSUV (r = 0.6451, p < 0.0001), %Glut-1 expression (r = 0.8341, p < 0.0001) and Glut-1 staining intensity (p = 0.827, p < 0.0001). The areaunder- curve value for LN differentiation using lymph node maxSUV was significantly higher in patients with a primary tumour maxSUV of >6 (AUC = 0.775, p = 0.0001).
High correlations between the primary tumours and metastatic LNs in NSCLC with respect to the Glut-1 mediated FDG uptake may be useful for mediastinal LN discrimination by FDG-PET.

Article Details

References

TÀI LIỆU THAM KHẢO
1. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997;112 :1480–6.
2. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348 :2500–7.
3. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27 :1778–85.
4. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004; 25:11–7.
5. Mamede M, Hig ashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancer s and inflammatory lesions of the lung. Neoplasia 2005; 7:369–79.
6. Higashi K, Ueda Y, Ayabe K, et al. FD G PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with his topatholog ical features. Nucl Med Commun 2000; 21:707–14.
7. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deox y-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201–6.
8. Higashi K, Ueda Y, Arisaka Y, et al. 18F- FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39–45.
9. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23 :865–70.
10. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23 :1136–43.
11. Nguyen XC, Lee WW, Chung JH, et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007; 62:214–9.
12. Higashi K, Ito K, Hiramatsu Y, et al. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005; 46:267–73.
13. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastina l (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with non-small-cell lung cancer. Ann Thorac Surg 2007;83 :1826–9 [discussion 1829-30].
14. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 2004; 45 :999–1003.
15. Chung JH, Lee WW, Park SY, et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol 2006; 32:989–95.
16. Lee WW, Chung JH, Jang SJ, et al. Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol 2006;94 :607–13.
17. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FD G uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008; in press. doi:10.1016/j.lungc an.2007.11.012.
18. Wahl R. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl R, editor. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 100–10.
19. .
20. Mountain CF, Dresler CM. Regional lymph node classifi cation for lung cancer staging. Chest 1997;111 :1718–23.